ARC Regulatory

Executive Summary

ARC Regulatory is a UK-based consulting firm specializing in regulatory compliance and clinical research support for precision medicine, companion diagnostics (CDx), and in vitro diagnostics (IVD). Founded in 2009, the company helps clients navigate complex global regulatory landscapes, ensuring data integrity and compliance to accelerate biomarker-driven clinical research. With the IVDR transition and tightening FDA guidance on CDx, ARC is well-positioned to capture demand from diagnostic and pharmaceutical companies seeking expert navigation of evolving rules. As a private, bootstrapped firm, ARC has no disclosed funding and limited public traction, but its niche focus and long track record signal resilience. The upcoming EU IVDR full enforcement deadline in May 2026 and potential FDA modernization of CDx regulations represent significant tailwinds. However, the company's lack of scalability beyond consulting services and sensitivity to regulatory cycles may limit growth. Conviction is moderate pending evidence of revenue growth or market share gains.

Upcoming Catalysts (preview)

• Q2 2026EU IVDR Full Enforcement Deadline95% success
• Q3 2026FDA New Guidance on Companion Diagnostics80% success